key: cord-1037624-1lgp82tw
authors: Sasaki, Lizandra Paravidine; Fernandes, Geraldo Magela; Silva, Ângelo Pereira da; Motta, Felipe; Siracusa, Clara; Rabelo, Isadora Pastrana; Junior, Agenor dos Santos; França, Paulo; Kurisky, Patricia; Tristão, Rosana Maria; de Albuquerque, Cleandro; Gomes, Ciro; Maria da Mota, Licia; Zaconeta, Alberto
title: Cerebrospinal Fluid Analysis Of Pregnant Women At Early Stages Of COVID-19
date: 2022-05-23
journal: Taiwan J Obstet Gynecol
DOI: 10.1016/j.tjog.2022.03.043
sha: d8ba917536151af341034cd19f29cfb097df061a
doc_id: 1037624
cord_uid: 1lgp82tw

Objective To determine the presence or absence of SARS-CoV-2 in the cerebrospinal fluid of pregnant women at early stages of COVID-19. Materials and methods We conducted a prospective observational study with pregnant women undergoing cesarean section and real-time polymerase chain reaction to SARS-CoV-2 was performed in the cerebrospinal fluid in the early stages of COVID-19. Results Fourteen pregnant women, whose COVID-19 symptoms started between four to 18 days prior to delivery, were included. Eleven of the women reported anosmia, dysgeusia, and headaches and there were two fatal cases. SARS-Cov-2 was not present in the cerebrospinal fluid of these COVID-19 patients with early neurological symptoms, even in severe cases. Conclusion Our study suggests that peripheric cell damage and parainfectious phenomena may predominate over direct central nervous system injury in the pathophysiology of COVID-19 related early neurological symptoms on pregnant women.

Results: Fourteen pregnant women, whose COVID-19 symptoms started between four to 18 60 days prior to delivery, were included. Eleven of the women reported anosmia, dysgeusia, and 61 headaches and there were two fatal cases. SARS-Cov-2 was not present in the cerebrospinal 62 fluid of these COVID-19 patients with early neurological symptoms, even in severe cases. Zaragoza, Spain) kits, whose detection limit is 4 copies per reaction. 116 117

Fourteen pregnant women, whose COVID-19 symptoms started 4-18 days prior to 119 delivery, were included. Among them, ten, three, and one had mild, severe, and critical diseases, 120 respectively. Eleven reported anosmia, dysgeusia or headaches (Table) . 121

There were two fatal cases, a critical disease patient who died 18 days postpartum due 122 to respiratory failure and a severe disease patient whose respiratory condition was improving 123 when she suddenly developed recurrent generalized tonic-clonic seizures and died 13 days 124 postpartum. Angiotomography findings indicated posterior reversible encephalopathy 125 syndrome, with no signs of thrombosis or hemorrhage. The CSF was SARS-CoV-2 RNA 126 negative in all patients. 127 J o u r n a l P r e -p r o o f remains unclear whether and how the virus crosses the blood-brain barrier (BBB). 7, 8, 9 . Since 130 severe neurological manifestations of COVID-19 typically occur after the acute phase, 131 microbiological examination of the CSF was rarely performed in the early stages of the 132 disease. 10 However, during the first wave of the COVID-19 we had the opportunity to analyze 133 the CSF of pregnant women whose symptoms had started between four and eighteen days. 134

Our results indicate that SARS-CoV-2 is not present in the CSF of COVID-19 patients 135 with early neurological symptoms and therefore these symptoms may be not attributable to 136 direct viral injury to the central nervous system. 137

As headache is a ubiquitous, non-specific symptom frequently seen in other infectious after several days to weeks. This sudden onset, followed by a rapid recovery, is a strong 142 argument against neuronal damage as a cause, given the time course of neuronal regeneration. 143

Additionally, there is currently no evidence that the SARSCoV-2 virus itself can reach the brain 144 in the acute phase of anosmia. 11 Therefore, since SARS-CoV-2 enters human cells via the 145 angiotensin-converting enzyme 2 (ACE 2) receptor that is expressed in the sustentacular cells 146 of the olfactory epithelium but not in the olfactory sensory neurons, it has been proposed that 147 anosmia and dysgeusia are secondary to olfactory epithelium damage. 11 148

Our data are in line with the growing evidence suggesting that parainfectious immune-149 mediated mechanism predominate over direct neurological injury in the pathophysiology of 150 COVID-19 related neurological symptoms. 1, 12, 13 However, more studies are needed to 

Lifting the mask on neurological manifestations of COVID-19

Patients 161 with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA 162 levels in the cerebrospinal fluid

Neurologic features in severe SARS-CoV-2 infection

Three-steps" infection model and CSF diagnostic implication

Characteristics and 171 outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection

SARS-CoV-2 crosses the blood-brain 179 barrier accompanied with basement membrane disruption without tight junctions alteration

A first case of 182 meningitis/encephalitis associated with SARS-Coronavirus-2

Multiorgan and Renal Tropism of SARS-CoV-2

PANDEMIC and the IGNITE study groups. Cerebrospinal fluid findings in COVID-19

patients with neurological symptoms

Anosmia in COVID-19: Underlying Mechanisms and 192 Assessment of an Olfactory Route to Brain Infection

Evidence of the COVID-19 virus targeting the 195 CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

Abbreviations: a CSF, cerebrospinal fluid; b PCR, polymerase chain reaction; c Ab, antibodies; d CT, computed tomography; e Death on the 18th day postpartum due to respiratory failure; f Death on the 13th day postpartum due to multiple organ failure, g NA, not applicable